New drug combo aims to stop breast Cancer's comeback

NCT ID NCT05467891

Recruiting now Disease control Sponsor: Oana Danciu Source: ClinicalTrials.gov ↗

Summary

This study is testing whether adding the drug ribociclib to standard hormone therapy can better prevent breast cancer from returning in patients who have already had a local recurrence surgically removed. The trial will enroll 200 adults with hormone-sensitive, HER2-negative breast cancer that came back in the breast or nearby lymph nodes but has been treated with surgery and/or radiation. Participants will take ribociclib pills daily for 3 years and hormone therapy for 5 years to see if this combination keeps the cancer away longer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HORMONE RECEPTOR-POSITIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Medical University of South Carolina
RECRUITING

Charleston, South Carolina, 29425, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
New York University Clinical Cancer Center
RECRUITING

New York, New York, 10016, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States

Contact

Contact Email: •••••@•••••
Orlando Health Cancer Institute
ACTIVE_NOT_RECRUITING

Orlando, Florida, 32806, United States
Parkview Research Center
RECRUITING

Fort Wayne, Indiana, 46845, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Penn State Cancer Institute
RECRUITING

Hershey, Pennsylvania, 17033, United States

Contact Email: •••••@•••••

Contact
Providence Portland Medical Center
RECRUITING

Portland, Oregon, 97213, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
Rutgers Cancer Institute of New Jersey
RECRUITING

New Brunswick, New Jersey, 08903, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
Tufts Medical Center
RECRUITING

Boston, Massachusetts, 02111, United States

Contact

Contact Email: •••••@•••••
University of Alabama at Birmingham
RECRUITING

Birmingham, Alabama, 35294, United States

Contact Email: •••••@•••••

Contact
University of Arizona
RECRUITING

Phoenix, Arizona, 85004, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
University of Illinois Cancer Center
RECRUITING

Chicago, Illinois, 60612, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
University of Iowa Hospitals and Clinics
RECRUITING

Iowa City, Iowa, 52242, United States

Contact Email: •••••@•••••

Contact
University of Michigan Health System
RECRUITING

Ann Arbor, Michigan, 48109, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
University of Michigan Health-West
TERMINATED

Wyoming, Michigan, 49519, United States
University of Nebraska Medical Center
RECRUITING

Omaha, Nebraska, 68198, United States

Contact

Contact Email: •••••@•••••
University of New Mexico Comprehensive Cancer Center
RECRUITING

Albuquerque, New Mexico, 87102, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
University of Virginia Health System
RECRUITING

Charlottesville, Virginia, 22908, United States

Contact Email: •••••@•••••

Contact
University of Wisconsin
RECRUITING

Madison, Wisconsin, 53705, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Virginia Commonwealth University
RECRUITING

Richmond, Virginia, 23298, United States

Contact Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

HER2-NEGATIVE BREAST CANCER HORMONE RECEPTOR-POSITIVE BREAST CANCER LOCOREGIONAL RECURRENCE